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Sinceepigeneticalterationsarebelievedtobeinvolvedintherepressionoftumorsuppressorgenesandpromotionoftumorigenesis
in ovarian cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic
approach. In this review, we discuss the biologic and therapeutic eﬀects of HDAC inhibitors (HDACIs) in treating ovarian
cancer. HDACIs were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and expression of genes related to
the malignant phenotype in a variety of ovarian cancer cell lines. Furthermore, HDACIs were able to induce the accumulation of
acetylated histones in the chromatin of the p21WAF1 gene in human ovarian carcinoma cells. In xenograft models, some of HDACIs
have demonstrated antitumor activity with only few side eﬀects. Some clinical trials demonstrate that HDACI drugs provide an
important class of new mechanism-based therapeutics for ovarian cancer. In this review, we discuss the biologic and therapeutic
eﬀects of HDACIs in treating ovarian cancer, especially focusing on preclinical studies and clinical trials.
1.Introduction
Ovarian cancer is the most lethal gynecologic malignancy
[1]. Early-stages of ovarian cancer are frequently asymp-
tomatic and diﬃcult to detect and thus diagnosis usually
occurs after the disease advanced. The search for agents
eﬀective in the treatment of either advanced or recurrent
ovarian cancer has been disappointing. To date, platinum
andpaclitaxeldemonstratethegreatesteﬃcacy[1].However,
although reported response rates have been as high as 70%,
the duration of response remains brief. In patients with
stage III and IV disease, the median duration of response
(as measured by progression free survival) following ﬁrst
line therapy is approximately 18 months (reviewed in
[2]). Therefore, innovative approaches are needed for the
treatment of ovarian cancer.
1.1. Histone Modiﬁcation. One of the most important mech-
anisms in chromatin remodeling is the posttranslational
modiﬁcation of the N-terminal tails of histones by acetyla-
tion, which contributes to a “histone code” determining the
activityoftargetgenes[3].Transcriptionallysilentchromatin
is composed of nucleosomes in which the histones have low
levels of acetylation on the lysine residues of their amino-
terminal tails. Acetylation of histone proteins neutralizes the
positive charge on lysine residues and disrupts nucleosome
structure, allowing unfolding of the associated DNA with
subsequent access by transcription factors, resulting in
changes in gene expression. Acetylation of core nucleosomal
histones is regulated by the opposing activities of histone
acetyltransferases(HATs)andhistonedeacetylases(HDACs).
HDACs catalyze the removal of acetyl groups on the amino-
terminal lysine residues of core nucleosomal histones, and
this activity is generally associated with transcriptional
repression. Aberrant recruitment of HDAC activity has been
associated with the development of certain human cancers
[4]. HDAC inhibitors (HDACIs) can inhibit cancer cell
growthinvitroandinvivo,revertoncogene-transformedcell
morphology, induce apoptosis, and enhance cell diﬀerentia-
tion [5].
1.2. Mechanisim of Action of HDACI. HDACs catalyze the
removal of acetyl groups from the chromatin core histones.2 Journal of Oncology
HDACs induce neutralization of the charge on the histones
which allows the phosphate backbone of the DNA to
open up and therefore facilitate the transcription of many
genes, including tumor suppressor genes silenced in cancer.
Moreover, acetylation of histones facilitates destabilization
of DNA-nucleosome interaction and renders DNA more
accessible to transcription factors [6]. In parallel to eﬀects
on gene expression and diﬀerentiation, HDACIs have also
been shown to be eﬃcient inducers of apoptosis in several
cellularsystems[7].Theprecisemechanismsofthiseﬀectare
underinvestigation,withsuggestionsrangingfromeﬀectson
cellular networks to oxidative stress induction and to DNA
damage induction [8].
1.3. DiﬀerentClasses of Drug. Severalclassesof HDACIs have
been identiﬁed, including (a) organic hydroxamic acids (e.g.,
Trichostatin A (TSA) and suberoyl anilide bishydroxamine
(SAHA)), (b) short-chain fatty acids (e.g., butyrates and
valproic acid (VPA)), (c) benzamides (e.g., MS-275), (d)
cyclic tetrapeptides (e.g., trapoxin), and (e) sulfonamide
anilides [9] (see Table 1).
1.4. Postulated Downstream Eﬀects of Inhibition. HDACIs
markedly upregulated the level of p21WAF1 and p27KIP1
proteins, which were expressed at negligible levels in the
untreated ovarian cancer cell lines. Conversely, HDACIs
decreased the levels of cyclin D1 and cyclin D2. HDACIs
decreased bcl-2 levels. E-cadherin binds to β-catenin and
can act as a tumor suppressor gene; its promoter has CpG
islands which are frequently methylated in selected cancers.
Although some investigators believed that the expression
of E-cadherin can promote carcinogenesis from normal
ovarian surface epithelial cells unlike the other carcinomas
[10], HDACIs markedly increased the expression level of E-
cadherin in endometrial and ovarian cancer cells and exhibit
antiproliferative activity in these cells [11]( Figure 1).
2. PreclinicalInVitroStudies
SAHA (vorinostat) is one of the most promising HDACIs
in treatment of epithelial ovarian cancer. To date, three
studies have evaluated vorinostat in ovarian cancer. Takai
et al. elucidated for the ﬁrst time that vorinostat caused
cell cycle arrest and markedly induced apoptosis in nine
ovarian cancer cell lines [11]. Second, Sonneman et al.
found that vorinostat had cytotoxic activities and caspase-
3 activities in three ovarian cancer cell lines as well as
in primary cancer cells that were isolated from malignant
ascites collected from ﬁve patients with stage III ovarian
carcinomas. They also found that paclitaxel-resistant ovarian
cancer cell line (2780AD) cells were responsive to varinostat
[12]. Third, Cooper et al. reported that in an ovarian
cancer cell line, vorinostat decreased viability and increased
apoptosis similarly to paclitaxel, but the combination was
not statistically signiﬁcantly diﬀerent from the single agents
[13].
The anticonvulsant VPA has HDAC inhibitory activity
[14].VPAhasanextensivesafetyhistoryandwell-established
pharmacokinetics. In cell culture models, exposure to VPA
resultsindose-dependentcellcyclearrestaswellasapoptosis
in nine ovarian cancer cell lines [11]. Furthermore, Lin et
al. suggested that VPA synergizes with cytotoxic anticancer
agents [15].
HDACIs that demonstrated antiovarian cancer activity
in single agent are TSA [11], vorinostat [11], CBHA [16],
scriptaid[17],sodiumbutyrate[11],VPA[11],MS-275[18],
M344 [19], apicidin [20], and PDX101 [21].
There are some combination studies in ovarian cancer
cells looking at HDACIs in combination with multiple
diﬀerent agents; these include traditional cytotoxic agents
(paclitaxel [12, 13, 21, 22], docetaxel [21], cisplatin [15],
carboplatin [21]), biologic agents (bortezomib [23]), and
aspirin [19]. All of these combination studies in ovarian can-
cerseektocapitalizeonthemultiplediﬀerentmechanisms of
action of HDACIs in order to create a synergistic eﬀect with
the other modalities and to increase the tumoricidal impact.
3.PreclinicalInVivoStudies
We previously tested the ability of VPA to inhibit the
growth of human SK-OV-3 ovarian cancer tumors grow-
ing in immunodeﬁcient mice during 5 weeks of therapy
[11]. Administration of VPA remarkably suppressed the
growth of the tumors. During the study, all the mice were
weighed once per week. No signiﬁcant diﬀerences in the
mean weights, histology of internal organs, mean blood
chemistries including liver parameters and hematopoietic
values were found between diluent-treated mice and those
that received 5 weeks of therapy. It meant that there was
no side eﬀect during VPA treatment. Histological analysis
of these tumors from untreated mice revealed moderately
diﬀerentiated carcinomas with small foci of necrosis and
ﬁbrosis. Approximately 50%–60% of each of the tumor
sections from mice treated with VPA revealed necrosis
and histologic changes of apoptosis including formation of
a p o p t o t i cb o d i e s .T h e s et u m o r sw e r es a m p l e df o re x p r e s s i o n
of p21WAF1 using immunohistochemistry on formalin-ﬁxed
paraﬃn-embedded sections. SK-OV-3 ovarian cancer cells
treated with VPA showed strong nuclear staining. Control
cancer cells from untreated mice had negative or focal weak
staining for p21WAF1.p 2 1 WAF1 is cyclin dependent kinase
inhibitors (CDKIs) that bind to cyclin-dependent kinase
complexes and decrease kinase activity and may act as key
regulators of the G0/G1 accumulation (reviewed in [24]).
Qian et al. demonstrated that PXD101 displayed single-
agent antitumor activity on human A2780 ovarian cancer
xenografts which was enhanced when combined with car-
boplatin [21]. Cooper et al. reported that a nude mouse
ovarian cancer model found limited single agent eﬃcacy
with vorinostat; however, paclitaxel followed by vorinostat
and paclitaxel alone increased survival compared to either
vorinostat alone or vorinostat followed by paclitaxel [13].
These studies raised several questions regarding the optimal
sequencing of future combination therapy with HDACIs and
chemotherapy.Journal of Oncology 3
Table 1: Overview of frequently used histone deacetylase inhibitors being available for clinical and research purposes.
Substance groups Derivatives Isotype Study phase
Hydroxamates Trichostatin A (TSA) I, II
Suberoylanilide hydroxamic acid (SAHA,
vorinostat)
I, II, IV III
LBH589 (panobinostat) I, II, IV II
PCI24781 (CRA-024781) I, IIb I
LAQ824 I, II I
PXD101 (belinostat) I, II, IV II
ITF2357 I, II II
SB939 Unknown I
JNJ-16241199 (R306465) II
m-carboxycinnamic acid bishydroxamide
(CBHA)
Scriptaid
Oxamﬂatin
Pyroxamide
Cyclic hydroxamic acid containing peptides
(CHAPs)
Short chain fatty acids Butyrate I, IIa II
Valproate I, IIa II
AN-9 II
OSU-HDAC42
Benzamides MS-275 (entinostat) 1, 2, 3, 9 II
MGCD0103 1, 2, 3, 11 II
Pimelic diphenylamide 1, 2, 3
M344
N-acetyldinaline (CI-994) II
Cyclic tetrapeptides Apicidine I, II
Trapoxins
HC-toxin
Chlamydocin
Depsipeptide (FR901228 or FK228) (romidepsin) 1, 2, 4, 6 II
Sulfonamide anilides
N-2-aminophenyl-3-[4-(4-
methylbenzenesulfonylamino)-phenyl]-2-
propenamide
Others Depudecin
NDH-51
KD5150 Pan-HDACI
Class I: HDAC 1, 2, 3, 8; class IIa: HDAC 4, 5, 7, 9; class IIb: HDAC 1, 2, 3, 8; class III: HDAC 6, 10; class IV: HDAC 11.
4.ClinicalTrials
HDACIs require a signiﬁcant period of exposure (≥24
hours) to achieve maximum tumor cell killing in culture,
presumably because of their action as cell cycle agents.
Sequestration and elimination may also be problems in
vivo. Thus continuous administration may be required to
achieve eﬃcacy in the clinic [9]. Some HDACIs (e.g., TSA
and trapoxin) are of limited therapeutic use because of
poor bioavailability in vivo as well as toxic side eﬀects
at high doses. Sodium butyrate and phenylbutyrate are
degraded rapidly after IV administration (short half life) and
therefore require high doses exceeding 400mg/kg/day [25].
Furthermore, these compounds are not speciﬁc for HDACs
because they also inhibit phosphorylation and methylation
of proteins as well as DNA methylation [26].
There is only one phase I data including ovarian cancer
patients treated with HDACI. Camacho et al. conducted
phase I dose escalation clinical trial of phenylbutyrate
sodium administered twice daily to patients with advanced
solid tumors at Memorial Sloan-Kettering Cancer Center.
Administration of phenylbutyrate sodium in a twice-daily
infusion schedule is safe. The maximum tolerated dose is
300mg/kg/day [27].4 Journal of Oncology
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Figure 1: The mechanism of action of HDACIs against ovarian cancer [9].
The multi-institutional phase II trial assessed the activity
andtoxicityofanewhistonedeacetylaseinhibitor,vorinostat
in patients with recurrent or persistent epithelial ovarian,
or primary peritoneal carcinoma [28]. The initial dose
of vorinostat was 400mg orally daily and a cycle was
deﬁned as a period of 3 weeks (21 days) and was given
at a ﬁxed daily dose until progressive disease or adverse
eﬀects prohibited further therapy with this agent. The
primary endpoints were progression-free survival (PFS) at 6
months and toxicity. Two women of twenty-seven enrolled
patients survived progression-free over 6 months, with
one having a partial response. The estimated probability
of PFS for at least 6 months was 7.4% (90% C.I. was
1.3%–21.5%). Major grade 4 toxicities were leucopenia
and neutropenia (7%). While there has not been clear
evidence of QTc prolongation due to vorinostat in either
preclinical or clinical studies to date, isolated clinical events
of QTc prolongation have been reported for other HDAC
inhibitors [29]. This phase II GOG study of vorinostat
in recurrent ovarian cancer patients demonstrated that,
in this platinum-resistant or refractory patient population,
there is limited eﬃcacy for this drug as a single agent.
Authors discussed that it could be classiﬁed as a biologic
response modiﬁer rather than a traditional cytotoxic agent.
In ovarian cancer, the potential role for this drug may be
in overcoming chemotherapy resistance in recurrent disease
or in combination with paclitaxel and platinum agents in
the upfront treatment. Due to the nature of vorinostat, it
m a yb em o r ee ﬀective in low-volume disease for stabilization
or prevention of recurrence. Future preclinical and clinical
trials will need to focus on potential synergistic eﬀects
of vorinostat with other agents, particularly paclitaxel and
platinum agents.
Phase II study, single-arm study of hydralazine and
magnesium valproate added to the same schedule of
chemotherapy on which patients were progressing, has been
conducted [30]. Patients received hydralazine at 182mg for
rapid, or 83mg for slow, acetylators, and magnesium val-
proate at 40mg/kg, beginning a week before chemotherapy.
Response and toxicity were evaluated. Seventeen patients
were evaluable for toxicity and 15 for response. A clini-
cal beneﬁt was observed in 12 (80%) patients: four PR,
and eight SD. The most signiﬁcant toxicity was hemato-
logic.
There were two clinical presentations from ASCO 2008
with PDX101 (belinostat) both alone and in combination
with chemotherapy in ovarian cancer [31, 32]. Mackay et
al. demonstrated a phase II trial of belinostat in patients
with platinum resistant epithelial ovarian cancer (EOC) and
borderline ovarian tumors. Belinostat 1,000mg/m2/day was
administered IV on days 1–5 of a 21-day cycle. Tumor
response was assessed by RECIST and CA125 criteria
every 2 cycles. Of 18 patients with EOC, 9 patients have
SD, 6 progressive disease (PD), 3 are nonevaluable (NE),
and 2 remain on study. Of 12 patients with borderline
tumors, 1 patient had a partial response (PR), 9 SD,
and 2 are NE. 1 further patient had a CA125 response.
5 patients remain on study. The most frequent grade 3
adverse events (both patient groups) were bowel obstruc-
tion, thrombosis, dyspnea, fatigue, lymphopenia, elevated
ALP, and nausea. Belinostat shows promising activity in
borderline ovarian tumors. Finkler et al. conducted phase
II multicenter trial of belinostat, carboplatin, and paclitaxel
in patients with relapsed epithelial ovarian cancer. BelCaP
(Bel 1,000mg/m2 × 5 days; carboplatin AUC 5 × 1d a y3 ;
paclitaxel 175mg/m2 × 1 day 3) was given in 3-week cycles.
The primary endpoint was overall response rate (OR). OR
was 31%, including 1 complete response and 10 PR. In
addition, 16 patients (46%) had SD.Journal of Oncology 5
5. Conclusions
In this review we summarize recent studies on the use of
HDACIs especially in human ovarian cancer cells. Many
questions are currently still unanswered with respect to
HDACI speciﬁcities for deﬁnite tumor subtypes and the
molecular mechanisms underlying HDACI-induced diﬀer-
entiation, cell cycle arrest and apoptosis, and the regulation
mechanisms of the speciﬁc gene expression and recruitment
of HDAC complex to the speciﬁc promoter sites remain
still to be determined. Also, it is still unclear to what
extent diﬀerent HDACs exhibit diﬀerent and potentially
overlapping functions, and it is important to distinguish
the HDAC speciﬁcity of HDACIs for the development of
selective therapy on the molecular level. Certainly, further
work will be required to improve the understanding on
why transformed cells are more susceptible to the eﬀect of
HDACIs than normal cells. Also, combinations of HDACIs
with diﬀerentiation-inducing agents, with cytotoxic agents,
and even with gene therapy may represent novel therapeutic
strategies and new hope on the horizon in the treatment of
ovarian cancer.
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